{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:15:34Z","timestamp":1793643334951,"version":"4.5.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Henlius Biotech, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To evaluate the efficacy and safety of HLX01, a rituximab biosimilar, as combination therapy with methotrexate in Chinese patients with active rheumatoid arthritis who had inadequate responses to methotrexate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this double-blind, placebo-controlled phase 3 trial, biologic-na\u00efve patients with moderate-to-severe active rheumatoid arthritis and inadequate responses to methotrexate were randomized 2:1 to receive 1000 mg HLX01 or placebo intravenously on days 1 and 15. On the first day of weeks 24 and 26, patients in both groups received 1000 mg HLX01 via intravenous infusion. The primary endpoint was the American College of Rheumatology (ACR) 20 response rate at week 24. Secondary endpoints including efficacy, safety, immunogenicity, pharmacokinetics and pharmacodynamics were assessed up to week 48.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between 28 May 2018 and 11 September 2020, 275 patients were randomized to the HLX01 group (<jats:italic>n<\/jats:italic> = 183) or the placebo group (<jats:italic>n<\/jats:italic> = 92). At week 24, the proportion of patients achieving ACR20 response was significantly greater in the HLX01 group compared with the placebo group in the intention-to-treat population (60.7% <jats:italic>vs<\/jats:italic> 35.9%; <jats:italic>P<\/jats:italic> &lt; 0.001) and per-protocol set (60.3% <jats:italic>vs<\/jats:italic> 37.1%; <jats:italic>P<\/jats:italic> &lt; 0.001). Most secondary efficacy endpoints favoured HLX01 when assessed at weeks 12, 24, 36 and 48. Incidences of treatment-emergent adverse events were similar between groups. Infusion-related reactions occurred more frequently following the initial two doses of HLX01 than the subsequent doses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>HLX01 plus methotrexate improved clinical outcomes compared with placebo in Chinese patients with rheumatoid arthritis who had inadequate responses to methotrexate. This treatment regimen was well tolerated, showing comparable safety profiles to placebo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03522415\">NCT03522415<\/jats:ext-link>. Registered on 11 May 2018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02821-x","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T08:25:14Z","timestamp":1654849514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3883-2318","authenticated-orcid":false,"given":"Xiaofeng","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangping","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-ai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the HLX01-RA03 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meimei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cibo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqi","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongwen","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wufang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"2821_CR1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205\u201319.","journal-title":"N Engl J Med"},{"key":"2821_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685\u201399.","journal-title":"Ann Rheum Dis"},{"key":"2821_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13075-021-02599-4","volume":"23","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Stryker S, Liu M, Salim B, Rebello S, Gharaibeh M, et al. Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry. Arthritis Res Ther. 2021;23:236.","journal-title":"Arthritis Res Ther"},{"key":"2821_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1\u201325.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2821_CR5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1136\/ard.62.10.944","volume":"62","author":"D Aletaha","year":"2003","unstructured":"Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP, et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis. 2003;62:944\u201351.","journal-title":"Ann Rheum Dis"},{"key":"2821_CR6","first-page":"242","volume":"57","author":"Chinese Rheumatology Association","year":"2018","unstructured":"Chinese Rheumatology Association. 2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis. Zhonghua Nei Ke Za Zhi. 2018;57:242\u201351.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2821_CR7","unstructured":"RITUXAN\u00ae prescribing information [Internet]. U.S. Food and Drug Administration [cited 8 February 2022]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103705s5467lbl.pdf."},{"key":"2821_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","volume":"16","author":"R Giacomelli","year":"2017","unstructured":"Giacomelli R, Afeltra A, Alunno A, Baldini C, Bartoloni-Bocci E, Berardicurti O, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren\u2019s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017;16:911\u201324.","journal-title":"Autoimmun Rev"},{"key":"2821_CR9","unstructured":"MabThera product information [Internet]. European Medicines Agency [cited 17 March 2021]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mabthera#authorisation-details-section."},{"key":"2821_CR10","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793\u2013806.","journal-title":"Arthritis Rheum"},{"key":"2821_CR11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3899\/jrheum.090442","volume":"37","author":"PJ Mease","year":"2010","unstructured":"Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol. 2010;37:917\u201327.","journal-title":"J Rheumatol"},{"key":"2821_CR12","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1136\/ard.2009.119222","volume":"69","author":"SB Cohen","year":"2010","unstructured":"Cohen SB, Keystone E, Genovese MC, Emery P, Peterfy C, Tak PP, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis. 2010;69:1158\u201361.","journal-title":"Ann Rheum Dis"},{"key":"2821_CR13","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572\u201381.","journal-title":"N Engl J Med"},{"key":"2821_CR14","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab\u2019s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69:1629\u201335.","journal-title":"Ann Rheum Dis"},{"key":"2821_CR15","doi-asserted-by":"publisher","first-page":"e47373","DOI":"10.1371\/journal.pone.0047373","volume":"7","author":"B Wu","year":"2012","unstructured":"Wu B, Wilson A, Wang FF, Wang SL, Wallace DJ, Weisman MH, et al. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in China. PLoS One. 2012;7:e47373.","journal-title":"PLoS One"},{"key":"2821_CR16","doi-asserted-by":"crossref","unstructured":"Frisell T, Dehlin M, Di Giuseppe D, Feltelius N, Turesson C, Askling J et al. Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. Rheumatology (Oxford). 2019;58(8):1367\u201377.","DOI":"10.1093\/rheumatology\/key433"},{"key":"2821_CR17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/19420862.2019.1578147","volume":"11","author":"Y Xu","year":"2019","unstructured":"Xu Y, Xie L, Zhang E, Gao W, Wang L, Cao Y, et al. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera\u00ae. MAbs. 2019;11:606\u201320.","journal-title":"MAbs"},{"key":"2821_CR18","doi-asserted-by":"crossref","unstructured":"Zeng X, Wang Y, Jiang Z, Zhang Z, He L, Zhang X et al. SAT0139\u2005A multicentre, randomised, double-blind, parallel active-controlled clinical trial comparing pharmacokinetics, pharmacodynamics, safety and exploratory efficacy between HLX01 and Europe-sourced rituximab as a new indication in Chinese moderate to severe patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(Suppl 2):1140.","DOI":"10.1136\/annrheumdis-2019-eular.3669"},{"key":"2821_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-020-00871-9","volume":"13","author":"Y Shi","year":"2020","unstructured":"Shi Y, Song Y, Qin Y, Zhang Q, Han X, Hong X, et al. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. J Hematol Oncol. 2020;13:38.","journal-title":"J Hematol Oncol"},{"key":"2821_CR20","unstructured":"Rituximab injection (HLX01) product insert [Internet]. National Medical Products Administration [cited 02 July 2021]. Available from: https:\/\/www.henlius.com\/upload\/202008\/13\/%E6%B1%89%E5%88%A9%E5%BA%B7%C2%AE%EF%BC%88%E5%88%A9%E5%A6%A5%E6%98%94%E5%8D%95%E6%8A%97%E6%B3%A8%E5%B0%84%E6%B6%B2%EF%BC%89%E8%AF%B4%E6%98%8E%E4%B9%A6.pdf."},{"key":"2821_CR21","unstructured":"Henlius receives NMPA approval for its first product HLX01 \u2013the beginning of a new era for biosimilar [Internet] [cited 10 June 2021]. Available from: https:\/\/www.henlius.com\/en\/NewsDetails-1867-26.html."},{"key":"2821_CR22","unstructured":"Statistical principles for clinical trails of chemical and biological agents [Internet]. National Medical Products Administration [cited 25 January 2021]. Available from: https:\/\/www.nmpa.gov.cn\/wwwroot\/gsz05106\/10.pdf."},{"key":"2821_CR23","unstructured":"Guidelines on Development and Evaluation of Biosimilars (drafting) [Internet]. National Medical Products Administration [cited 28 February 2021]. Available from: https:\/\/www.nmpa.gov.cn\/yaopin\/ypggtg\/ypqtgg\/20150228155701114.html."},{"key":"2821_CR24","unstructured":"Provisions for drug registration [Internet]. National Medical Products Administration [cited 25 January 2021]. Available from: https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/bmgzh\/20070710010101795.html."},{"key":"2821_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"2821_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727\u201335.","journal-title":"Arthritis Rheum"},{"key":"2821_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35\u201345.","journal-title":"Arthritis Rheum"},{"key":"2821_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13075-019-2046-0","volume":"21","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Glover J, Greenwald M, Porawska W, El Khouri EC, Dokoupilova E, et al. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension. Arthritis Res Ther. 2019;21:281.","journal-title":"Arthritis Res Ther"},{"key":"2821_CR29","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/art.38705","volume":"66","author":"MM Ward","year":"2014","unstructured":"Ward MM, Guthrie LC, Alba MI. Brief report: rheumatoid arthritis response criteria and patient-reported improvement in arthritis activity: is an American College of Rheumatology twenty percent response meaningful to patients? Arthritis Rheumatol. 2014;66:2339\u201343.","journal-title":"Arthritis Rheumatol"},{"key":"2821_CR30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909\u201320.","journal-title":"Ann Rheum Dis"},{"key":"2821_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","volume":"52","author":"J Listing","year":"2013","unstructured":"Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52:53\u201361.","journal-title":"Rheumatology (Oxford)"},{"key":"2821_CR32","unstructured":"Global tuberculosis reports [Internet]. World Health Organization [cited 28 Feburary 2021]. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports."},{"key":"2821_CR33","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/rheumatology\/key023","volume":"57","author":"AI Rutherford","year":"2018","unstructured":"Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2018;57:997\u20131001.","journal-title":"Rheumatology (Oxford)"},{"key":"2821_CR34","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1016\/S2665-9913(20)30033-3","volume":"2","author":"L Garcia-Montoya","year":"2020","unstructured":"Garcia-Montoya L, Villota-Eraso C, Yusof MYM, Vital EM, Emery P. Lessons for rituximab therapy in patients with rheumatoid arthritis. Lancet Rheumatol. 2020;2:e497\u2013509.","journal-title":"Lancet Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02821-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02821-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02821-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T08:26:21Z","timestamp":1654849581000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02821-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2821"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02821-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"9 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice guidelines, and local applicable regulatory requirements. The study protocol and informed consent were approved by the independent ethics committee at each participating site. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ying Li, Qingyu Wang and Jun Zhu are employees of Shanghai Henlius Biotech, Inc. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}